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4I Study rationale and methods
In recent years, environmental signals from both formal 
and informal research and monitoring sources have been 
indicating critical new developments within Europe’s new 
psychoactive substances (NPS) market. These include 
signs of increased and problem use of NPS among a range 
of demographic groups, including the use of synthetic 
cathinones by opioid and amphetamine injectors, the 
injection of synthetic cathinones by certain subgroups of 
men who have sex with men, reports of potent new 
synthetic opioids found in heroin products, and the use of 
synthetic cannabinoids by marginalised populations in 
some countries.
To investigate the circumstances and impact of these 
developments, a targeted rapid information assessment or 
‘trendspotter’ study was initiated by the European 
Monitoring Centre for Drugs and Drug Addiction 
(EMCDDA) and carried out between July and October 
2016.
The study aimed to map and increase understanding of 
high-risk drug use and NPS in Europe, including the range 
of forms this may take, the underlying facilitating factors, 
and associated harms and consequences. Specifically, it 
aimed to explore:
• the main high-risk user groups and their characteristics;
• clusters, patterns and trends in use;
• primary substances/products used and their effects;
• associated harms and deaths;
• external triggers and motivations for use.
In terms of methodology, the study was divided into two 
phases. The first phase involved a round of data collection 
by an EMCDDA team, including a literature review and the 
conducting of online surveys. The second phase centred 
on data collection and analysis. The analysis took place 
during an expert meeting, held in Lisbon on 20–21 
October 2016. This event was attended by 15 invited 
experts from 11 countries, who shared information and 
contributed to an in-depth analysis of the topic, providing 
insights from a range of perspectives including drug 
research and monitoring, front-line service provision, 
forensics, law enforcement and health.
The trendspotter study methodology utilises a range of 
different investigative approaches and data collection 
from multiple sources (Mounteney et al., 2015). This study 
incorporated three internet surveys (one among national 
focal points in 30 countries; one among experts attending 
the meeting; and one in an EMCDDA trendspotter 
network), ad hoc data collection among prison experts, 
a non-systematic review of the international literature, grey 
literature and available monitoring data, 15 expert 
presentations, and findings from three facilitated working 
groups. Analysis was based on triangulation of these 
information sources, with a view to providing as complete 
High-risk drug use definition — the study took as 
a starting point a focus on NPS use among:
a) high-risk users of opioids, stimulants and cannabis (1)
who switch to NPS use or incorporate NPS in their
polydrug use patterns;
b) people who inject NPS or use them in other
potentially harmful ways (including slamming);
c) people experiencing problems/entering treatment for
NPS-related problems;
d) marginalised or vulnerable drug-using populations
(including homeless people, prisoners, people with
mental health problems etc.).
Exclusion criteria — experimental use, occasional use, 
psychonauts, use not associated with health and social 
problems.
(1) See the EMCDDA website: emcdda.europa.eu/activities/hrdu
New psychoactive substance definition — the study 
took as a starting point a focus on non-controlled 
and recently controlled new psychoactive 
substances, in particular (but not exclusively) 
synthetic cathinones, synthetic cannabinoid receptor 
agonists (SCRAs), new synthetic opioids and new 
benzodiazepines.
Exclusion criteria — established illicit drugs including 
GHB (gamma-hydroxybutyrate), GBL (gamma-
butyrolactone) and ketamine (unless reported in 
problem polydrug use patterns with NPS). Fentanyl (as 
either a medicinal product or an illicit drug) is 
excluded, although many fentanyl derivatives are 
included as NPS.
Definitions used in this study
5and verified a picture as possible. The combination of 
routine and survey data with key informant reports and 
scientific literature provided a rich and in-depth view of 
a complex and differentiated phenomenon. This report 
summarises the study findings and conclusions. Where 
results are based on the literature, references are cited; 
otherwise findings are based on EMCDDA and national 
monitoring and the qualitative sources described above.
I  The substances: which NPS are linked with high-risk use?
I Synthetic cannabinoid receptor agonists
Synthetic cannabinoid receptor agonists (SCRAs) 
emerged over the past decade as an alternative to 
cannabis. This group of substances mimics the effects of 
THC (delta-9-tetrahydrocannabinol), which is the 
substance that is primarily responsible for the major 
psychoactive effects of cannabis (Fantegrossi et al., 2014). 
However, while THC is a weak partial agonist of 
cannabinoid receptors in the brain, SCRAs are potent full 
cannabinoid receptor agonists and most are very potent 
cannabinoid receptor type 1 (CB
1
)
 
agonists (Seely et al., 
2013).
Little is known about the pharmacological properties of 
SCRAs. It is possible that, apart from high potency, some 
could have particularly long half-lives, potentially leading to 
a prolonged psychoactive effect. However, because of the 
wide chemical diversity of SCRAs it is currently not 
possible to extrapolate pharmacological properties 
between, and potentially within, different SCRA classes 
(Lovett et al., 2015a).
SCRAs have sometimes been grouped under the street 
name ‘spice’ or ‘spice products’. The actual substances 
identified vary widely even within spice products with the 
same name, making it hard to establish the most used 
SCRAS. The most commonly seized in recent years have 
been AM-2201, MDMB-CHMICA, AB-FUBINACA, MAM-
2201 and XLR-11 (5F-UR-144).
When they first emerged SCRAs were predominantly 
seized as herbal smoking blends, but recently they have 
been increasingly seized in powder form, and they have 
also been found in tablet form and liquids. The powders 
are used to manufacture ‘legal high’/spice products and 
small quantities may represent millions of doses. The 
typical amount in a packet of spice is around 3 g (Fattore 
and Fratta, 2011).
The present study identified the use of SCRAs among 
high-risk drug-using populations including prisoners in 
around two thirds (19) of the EMCDDA reporting countries: 
Belgium, Bulgaria, Croatia, the Czech Republic, Finland, 
France, Germany, Greece, Hungary, Ireland, Italy, Latvia, 
Poland, Portugal, Romania, Slovenia, Sweden, Turkey and 
the United Kingdom.
By the end of 2016 the European Early Warning System 
(EU EWS) was routinely monitoring over 620 substances 
in EU Member States, Norway and Turkey. In 2016, 66 
NPS were formally notified for the first time.
The largest substance categories monitored by the EU 
EWS are the synthetic cannabinoids or SCRAs (over 160 
substances, including 11 new cannabinoids reported in 
2016), followed by the synthetic cathinones (over 100 
substances, 14 reported for the first time in 2016). 
Overall, 25 new opioids have been detected on Europe’s 
market since 2009, including nine reported for the first 
time in 2016. Similar low-level but increasing trends 
have been observed with the number of benzodiazepine 
derivatives available in recent years: six were detected 
for the first time in Europe in 2016.
In 2015, almost 80 000 seizures of NPS were reported. 
Together SCRAs and synthetic cathinones accounted 
for 60 % of all NPS seizure cases in 2015 (over 47 000). 
The number of seizures of new synthetic opioids 
remains relatively low.
Information received by the EU EWS also highlights the 
increase in reports of serious adverse events, including 
mass intoxications, deaths and outbreaks of infections 
associated with the use of NPS. In 2015, 17 public 
health-related alerts (including updates) were issued to 
the EU EWS network, addressing public health 
concerns, such as deaths associated with the use of 
potent synthetic opioids; clusters and outbreaks of 
intoxications associated with SCRAs; and infections 
among people who inject drugs, including NPS.
EU Early Warning System on new psychoactive substances
6I Synthetic cathinones
Synthetic cathinones were first detected in Europe in 2008 
and have emerged in recent years as a new class of stimulant 
drug in many European countries. These substances are 
ring-substituted phenylethylamines with a substitution of 
a ketone group at the β-carbon position. Different R-group 
substitutions give rise to a large list of synthetic cathinones, 
and many of them are identical except for the β-carbon 
ketone group (Spiller et al., 2011). These substances are 
often seen as an alternative to MDMA, amphetamines and 
cocaine because of their stimulant psychoactive effects. Very 
little is known about the pharmacokinetics and 
pharmacodynamics of synthetic cathinones, although, like 
amphetamines and cocaine, they are thought to act on the 
central nervous system, promoting release of monoamine 
neurotransmitters, and most likely inhibit their reuptake 
(Baumann et al., 2013; Dorairaj et al., 2012).
In Europe, synthetic cathinones have been sold online and 
in shops labelled as ‘plant food’ and ‘bath salts’ so that 
sellers can circumvent sales regulations. The most widely 
used synthetic cathinones in the context of problem drug 
use (as well as in recreational settings) in Europe are 
mephedrone (4-MMC), 3-MMC (closely related in structure 
to mephedrone), 4-MEC, pentedrone, and pyrovalerone 
derivatives such as MDPV or alpha-PVP. The most 
commonly seized synthetic cathinone in recent years 
include mephedrone and its isomers 3-MMC and 2-MMC, 
as well as pentedrone and alpha-PVP.
This analysis identified reports of the problematic use of 
synthetic cathinones in half of the countries reporting to 
the EMCDDA (Belgium, Czech Republic, Finland, France, 
Germany, Greece, Hungary, Ireland, Italy, Poland, Romania, 
Slovenia, Spain, Sweden and United Kingdom).
I New synthetic opioids
Synthetic opioids are a broad family of pain relievers and 
anaesthetics acting predominantly at the mu (μ) opioid 
receptor, but also at the sigma (δ) and kappa (κ) opioid 
receptors. Like opiates (e.g. heroin, opium and morphine) 
and semi-synthetic opioids (e.g. hydrocodone, 
hydromorphone, oxycodone and oxymorphone), synthetic 
opioids produce effects such as respiratory depression, 
analgesia, hypothermia, sedation, euphoria, drowsiness 
and miosis. The strength of physiological and psychological 
effects differs depending on the particular synthetic opioid 
and the type of receptor that is activated or inhibited.
In Europe, new synthetic opioids may be sold as heroin to 
unsuspecting users or as ‘synthetic heroin’ or ‘research 
chemicals’. The main new synthetic opioids currently being 
identified are fentanyl derivatives (e.g. acetyl fentanyl, 
acryloylfentanyl, carfentanyl and furanylfentanyl) and other 
opioids such as AH-7921, MT-45 and U-47700. Specific 
recent examples include seizures of carfentanyl found with 
heroin, and ocfentanil (with caffeine and paracetamol) sold 
as heroin. Acetyl fentanyl has also been found in the form 
of a nasal spray. MT-45 has been found in Belgium, 
Germany and Sweden, mostly in powder form, but also in 
herbal smoking mixtures along with a SCRA. Information 
about 42 deaths associated with acryloylfentanyl was 
reported in 2016 to the EMCDDA by four Member States: 
Denmark (1 case), Finland (1), Latvia (1) and Sweden (39).
New synthetic opioids have been identified by forensic 
analysis (seizures and deaths) in almost two thirds of 
reporting countries (Belgium, Bulgaria, Croatia, Cyprus, 
Estonia, Finland, France, Germany, Hungary, Ireland, 
Latvia, Luxembourg, Norway, Poland, Portugal, Slovakia, 
Spain, Sweden, United Kingdom).
I Benzodiazepines
Benzodiazepines are a class of psychoactive drugs that 
enhance the effect of the neurotransmitter gamma-
aminobutyric acid (GABA) at the GABA
A
 receptor, resulting 
in sedative, hypnotic (sleep-inducing), anxiolytic (anti-
anxiety), anticonvulsant and muscle-relaxant properties.
The EU EWS monitors more than 20 new and controlled 
benzodiazepines. New benzodiazepines are sometimes used 
by counterfeiters to produce fake medicines that are sold in 
Europe. Examples of this practice include fake alprazolam 
tablets, intercepted in 2015, that were found to contain 
flubromazolam, and fake diazepam tablets which contained 
phenazepam. In some European countries, these counterfeit 
medicines have become an important part of the illicit drug 
market. In the United Kingdom, etizolam, a benzodiazepine-
type NPS, is reported to be available on the illicit market.
I NPS use among high-risk drug users
NPS use among groups of high-risk drug users such as opioid 
and stimulant injectors was a primary focus for this study. 
This group is often in touch with treatment or low-threshold 
services and consequently some limited information may be 
available. In addition, patterns of NPS use among 
marginalised, vulnerable or socially disadvantaged groups, 
including homeless people, unemployed people and people 
with mental health problems, were also of concern. Overall, 
information on the use of NPS among these populations is 
7very fragmented and incomplete, and the availability of data 
on NPS use by these populations is scarce.
It is important to clarify that, overall, reports of use of NPS 
among high-risk drug users are rare in Europe, suggesting that 
prevalence is likely to be low. Nevertheless, 22 of the 30 
countries monitored by the EMCDDA do report the existence 
of some form of NPS use among their high-risk drug-using 
populations. Four countries (Austria, Cyprus, Luxembourg, 
Netherlands) report no documented NPS use among their 
high-risk drug users, while no information was available for 
four countries (Estonia, Lithuania, Malta, Slovakia) (Figure 1). 
From the available information, the NPS most commonly used 
among high-risk drug users appear to be synthetic cathinones, 
more specifically mephedrone, MDPV, alpha-PVP, pentedrone 
and 3-MMC. The second most frequently reported category of 
NPS is SCRAs, followed by synthetic opioids.
FIGURE 1
Use of NPS by high-risk drug users in the European Union, 
Norway and Turkey (2016)
Use of NPS by high-risk
drug users: No dataReported Not reported
I Prevalence of NPS use among high-risk drug users
No Europe-wide estimates exist for current or lifetime use 
of NPS among high-risk drug users, and only a small 
number of countries, including Belgium and the Czech 
Republic, have national estimates of the prevalence of NPS 
use among high-risk drug users. In Belgium, last year NPS 
prevalence in high-risk drug users was on average 26 %, 
with SCRAs (19 %) and mephedrone (12.5 %), 2C-B (9 %), 
methoxetamine (MXE, 6 %), MDPV (4.7 %) and 
4-fluoroamphetamine (4-FA, 4.3 %) the most frequently
used by the needle and syringe programme population
(Windelinckx, 2015). In the Czech Republic, one third of
high-risk drug users have reportedly used a cathinone or
phenethylamine at least once (and 10.5 % used them in
the last 12 months) but a very low proportion report them
as their primary drug (0.2 %). In Hungary, before 2010,
approximately half of the clients of needle/syringe
programmes injected heroin and half injected
amphetamine. By 2014, over two thirds (68 %) of them
reported injecting an NPS as their main drug.
In the United Kingdom, 5.9 % of those participating in the 
Unlinked Anonymous Monitoring Survey during 2014 
reported that they had injected mephedrone during the 
preceding month, and 8.9 % had injected this drug at some 
point during the preceding year (PHE, 2015). In Scotland, 
a recent study explored NPS use among vulnerable 
populations (mental health service users, homeless people, 
people who injected, at-risk young people and men who 
have sex with men) (n = 424) and found use of NPS to be 
widespread, with 59 % of respondents reporting that they 
had ever used NPS (MacLeod et al., 2016). Of those, 74 % 
reported having used NPS within the last six months. The 
most commonly used NPS were SCRAs (41 %) and benzo-
type NPS (41 %), while approximately one fifth reported 
taking stimulant-type NPS (21 %) and mephedrone (19 %).
Lifetime experience of NPS use has also been measured in 
high-risk drug using populations in some countries. A study 
Some insights into drug use prevalence among young 
people (aged 15–24) in Europe are provided by the 2014 
Flash Eurobarometer, which reports NPS lifetime prevalence 
of 8 % and last year use of 3 % (European Commission, 
2014). Last year prevalence of NPS use ranged from 0 % in 
Poland to 9.7 % in Ireland (EMCDDA, 2016a). Reported 
prevalence levels of NPS use among European students 
aged 15–16 years is provided by the 2015 European School 
Survey Project on Alcohol and Other Drugs (ESPAD) study. 
Overall, lifetime prevalence was reported to be 4 % and last 
year prevalence 3 %. Last year prevalence of NPS use 
ranged from 1 % in Belgium (Flanders), Denmark, Finland, 
the Netherlands, Norway and Portugal to 8 % in Estonia and 
Poland (ESPAD, 2016). It is notable that results from these 
two studies show no consistency within countries in terms 
of reported levels of NPS use.
Prevalence of NPS use among young people
8of opioid users in Croatia reported a lifetime prevalence of 
2.3 % for mephedrone, 2.9 % for SCRAs and 14.9 % for 
other new drugs, and this study concluded that opioid 
users did not transfer to NPS (Doležal, 2011).
In some European countries no evidence was found to 
support the existence of NPS use among high-risk drug 
users. In Luxembourg, for example, Grund et al. (2016) 
found no data to suggest that high-risk drug users using 
established drugs, such as heroin, had used NPS.
Data on treatment entrance can also provide some insight 
into people experiencing problems with drug use, including 
with NPS. However, the data here are sparse and under-
reporting in this area is likely. In 2015 around 3 200 clients, 
or fewer than 1 % of European clients entering specialised 
drug treatment, reported problems related to NPS. In the 
United Kingdom, around 1 500 clients entering drug 
treatment (or around 1 % of all drug clients) reported 
primary use of synthetic cathinones; Hungary and 
Romania also report relatively high numbers of NPS users 
entering drug treatment. On the basis of the estimates 
from the treatment units participating in the Hungarian 
national focal point 2015 treatment facility survey, at least 
26 % of clients treated had a SCRA problem, and 21 % 
reported problems linked to new stimulants, mainly 
synthetic cathinones. In Croatia, in 2014, the first year on 
which data on selected NPS use were collected from the 
clients in drug treatment, only four clients were registered 
for primary use of NPS, SCRAs in all cases.
I Patterns of NPS use among high-risk drug users
The ways NPS are administered vary, and routes of 
administration tend to be both substance and context 
specific. In many countries injection of synthetic 
cathinones is reported as a common route of 
administration among groups who otherwise inject opioids 
or stimulants. Such patterns of intravenous NPS use have 
been documented in Austria, Finland, Germany Hungary, 
Latvia, Slovenia, Sweden and the United Kingdom. SCRAs 
are most commonly smoked as herbal mixtures, but there 
are reports of these drugs being snorted, consumed in 
tablet form or used in vaporisers (as c-liquids).
Two important factors emerge with regard to the use of 
NPS among high-risk drug users. Firstly, NPS use mainly 
occurs in a context of polydrug use. This means that the 
drugs are used in combination with or in the same session 
as other substances including illicit opioids, stimulants and 
benzodiazepines and alcohol. For example, in Slovenia, 
a 2014 study found that 3-MMC tended to be used 
simultaneously with other opioids (Sande, 2016).
Secondly, in most but not all cases, new psychoactive 
substances are very rarely reported to be the primary drug 
used by high-risk drug-using groups. More often they are 
a secondary or tertiary drug, for example when the 
preferred substance is not available or to heighten the 
effect of other drugs. This means that it would be 
uncommon to find many high-risk NPS users per se, with 
the exception of specific groups in Hungary and some 
areas of the United Kingdom.
The substitution of an established illicit drug (usually 
heroin or amphetamines) with an NPS is another pattern of 
use reported among high-risk drug users. Poor availability, 
low purity and high prices may play a role here. This 
development has been observed in Hungary and United 
Kingdom, for example, during periods of heroin shortage. 
Here the replacement of established drugs with synthetic 
cathinones has been relatively well documented. An 
analysis of client data from Hungary’s biggest needle/
syringe programme reveals that heroin was mainly 
substituted with synthetic cathinones such as 
mephedrone, MDPV and pentedrone (Tarján, 2017). In 
Slovenia, the use of 3-MMC as a replacement for cocaine 
is also reported among intravenous opiate users (Sande, 
2016). Interestingly, reports from needle exchanges in the 
United Kingdom indicate that many of the heroin users 
who migrated to injecting stimulant NPS returned to heroin 
injection after a period, in response to the negative effects 
of the NPS.
NPS are also used as a complement or in addition to other 
licit or illicit substances. In Finland high-risk drug users 
have reportedly been using NPS intravenously, including 
the synthetic cathinones alpha-PVP and MDPV, alongside 
established substances (Tammi et al., 2011). For many of 
this group, MDPV is administered together with and in 
addition to amphetamines, alcohol, and medicinal 
products (Grund et al., 2016).
I SCRAs and marginalised groups
Whereas first-generation SCRAs or ‘spice products’ have 
been on the European drug markets since around 2008, 
largely associated with recreational use and ‘legal highs’ 
smoking mixtures, a more recent trend has seen a rise in 
the use of SCRAs in vulnerable groups, including 
treatment population, homeless people and prisoners. 
This new phenomenon has been reported in more than 
half of European countries. Examples cited by experts 
include the use of SCRAs among homeless and 
vulnerable groups in Dublin (and rural areas of Ireland), 
Scotland and London, and use by Roma populations in 
Finland.
9In addition, the problem use of SCRAs by vulnerable young 
people was highlighted by experts involved in this study 
and is a particular cause for concern. In Finland, there are 
reports of very young people injecting SCRAs, and the 
internet market — with the relative ease of online 
purchases — is mentioned as playing an important role in 
this early onset. In Sweden, SCRAs or spice have received 
media attention, with older drug users reportedly 
appearing on national television to warn younger users of 
the serious adverse consequences of these drugs.
I NPS use in prison
NPS use among prisoners is a relatively new but rapidly 
developing phenomenon and empirical data are currently 
scarce and patchy. Monitoring drug use among prisoners 
in general, and NPS use in particular at the European level, 
is complicated. There is a lack of common definitions, and 
different methodologies and study designs are applied.
There is, however, growing evidence to show that the use 
of SCRAs has become a serious problem in prisons in the 
United Kingdom, where the issue (including violence and 
non-fatal and fatal intoxications) is relatively well 
documented. Information on the situation in other EU 
countries is largely anecdotal. Drug-related and other 
problems inside prisons (e.g. assaults and suicides) have 
risen to record levels in the United Kingdom (HMIP, 2015; 
User Voice, 2016), and a large part of the disruptive 
behaviour has been linked to the harms caused by the use 
of NPS, in particular SCRAs (Centre for Social Justice, 
2015; HMIP, 2016).
In total, this study identified reports of NPS use amongst 
prisoners from 15 European countries. In addition to the 
United Kingdom, there is some evidence to suggest that 
NPS use in prison settings is a problem in Hungary, Latvia, 
Poland, Slovenia and Sweden. Anecdotal reports also 
document NPS use in prison in Bulgaria, Croatia, the 
Czech Republic, Germany, Ireland, Finland, France, 
Portugal and Romania. For other European countries, it 
remains unclear whether there is no NPS use in prison or 
no information is available (Figure 2).
The limited information available indicates that SCRAs are 
responsible for a large share of drug-related problems in 
prison in the United Kingdom and to some extent in other 
countries, including Hungary, Latvia, Slovenia and Sweden. 
SCRAs or spice were first identified by Her Majesty’s 
Inspectorate of Prisons (HMIP) as a serious problem in the 
United Kingdom in December 2011, but were not identified 
as a widespread issue until 2013 (HMIP, 2015). HMIP’s 
thematic survey (2015) found that 10 % of respondents 
had used spice in their current prison, compared with 13 % 
who had used cannabis. Spice was found to be the only 
drug whose self-reported prevalence of use was higher in 
prison than in the two months before prison (HMIP, 2015). 
A survey carried out by User Voice among 684 prisoners in 
England found that one in three prisoners reported use of 
spice in the last month, making it the most popular drug 
(User Voice, 2016).
It is not possible to compare estimates across countries, 
as different definitions and methodologies are used. The 
prevalence estimates for NPS use in prison among 
countries for which data are available range from less than 
2 % in Portugal to over 30 % in some prisons in the United 
Kingdom (User Voice, 2016), often depending on the type 
of prison involved. There are indications that NPS use in 
prison may be higher in men’s prisons than in women’s 
prisons, higher in remand prisons and lower in high-
security prisons.
The HMIP report highlights that different types of NPS 
user are identifiable in UK prison settings, including those 
with long drug careers, often homeless and in regular 
contact with the criminal justice system, as well as a group 
of young, relatively inexperienced users who may be 
initiating NPS use in prison (HMIP, 2015). The report notes 
cases in which prisoners, referred to as ‘spice pigs’, are 
used to test new SCRA products, to find out what 
quantities are safe and what effects can be marketed.
There are anecdotal reports about supply of SCRAs in 
a number of European prisons, including dealers throwing 
FIGURE 2
Use of NPS among prisoners in the European Union, 
Norway and Turkey
NPS use in prisons: No dataProblematic 
use indicated
Some 
indications
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packages over the prison wall, sometimes using drones or 
hiding the substances inside dead birds. Staff, prisoners 
and visitors are seen to play an important role in the supply 
of SCRAs in prison, including using body cavities or 
bringing it into prison in the form of saturated rice-paper. 
Recently there have been reports that SCRAs are sprayed 
on letters or children’s drawings and enter the prison by 
post.
The emergence of SCRA use in prisons in Europe raises 
a multitude of issues, including challenges on appropriate 
healthcare responses and the adequacy of detection 
techniques. There is an urgent need for a better 
understanding and monitoring of this situation, alongside 
training of staff to be able to handle SCRA-related 
problems, both health and behavioural, and the 
establishment of appropriate treatment and harm-
reduction programmes in prisons. A recent training tool on 
NPS management has been published by Public Health 
England, identifying the main issues to deal with to tackle 
NPS-related problems for prison staff, and mandatory 
drug-testing procedures have been revised for English 
prisons (PHE, 2015).
I  NPS and injection among men who have sex with men/slamming
The practice of stimulant drug injection, sometimes 
including synthetic cathinones, by a subgroup of men 
who have sex with men has raised public health 
concerns in recent years. This injection behaviour, 
generally referred to as ‘slam’ or ‘slamming’, primarily 
takes place in the context of sex parties (Batisse et al., 
2016; Kirby and Thornber-Dunwell 2013a,b; Stuart, 
2013). Synthetic cathinones, such as mephedrone, are 
sometimes used in combination with other drugs such as 
GHB (gamma-hydroxybutyrate), GBL (gamma-
butyrolactone), crystallised methamphetamine, cocaine 
and sildenafil, with the purpose of reducing inhibition 
and enhancing sexual experience (Abdulrahim et al., 
2016; Bourne et al., 2014). ‘Chemsex’ parties can last 
from a few hours to several days and participants usually 
engage in risky sexual practices with multiple partners, 
sometimes exchanging syringes and not using condoms, 
with a consequent increase in the risk of contracting 
sexually transmitted diseases and other blood-/body 
fluid-borne viral infections (McCall et al., 2015; Peyrière 
et al., 2013).
At the time of writing, a small number of studies 
documenting slamming practices have come from France, 
Spain and the United Kingdom. A recent survey of HIV-
positive patients attending 30 HIV clinics in England and 
Wales found that among the men who have sex with men, 
nearly a third (29 %) reported engaging in chemsex in the 
past year and 1 in 10 reported slamming (Bourne et al., 
2015; Daskalopoulou et al., 2014; Pufall et al., 2016). 
Studies have also been conducted in French cities 
(Batisse et al., 2016; Foureur et al., 2013). In addition, 
experts involved in this analysis report that the injection of 
NPS among men who have sex with men also occurred in 
Ireland, the Netherlands and Sweden.
Reports of slamming practices are also available from 
other European countries. In both the Czech Republic and 
Germany, the injection of stimulants among small 
populations of men who have sex with men is confirmed, 
but synthetic cathinones do not appear to be part of the 
cocktail of substances used. In Denmark, Finland and 
Greece, anecdotal evidence also suggests that some 
stimulant injection might be occurring among men who 
have sex with men. In Italy and Slovenia, mephedrone is 
reportedly available and used in the men who have sex 
with men scene but there is no clear evidence that it is 
being injected (see Figure 3).
There are concerns that the small group of men who have 
sex with men who may be experiencing problems linked to 
chemsex and slamming seem to be ‘off the radar’ of 
national drug agencies and community-based drug 
services (Pirona et al., 2017). Evidence suggests that those 
among this group with drug problems are more likely to be 
in contact with sexual health clinics or HIV/AIDS 
checkpoints, and rarely access drug treatment services 
FIGURE 3
Reports of injection and stimulant use among men who 
have sex with men in the European Union, Norway and 
Turkey
No data 
Synthetic cathinones
used, no data for 
injection
Injection of stimulants,
not including synthetic 
cathinones
Injection of stimulants,
including synthetic
cathinones
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(Lovett et al., 2015b). In this area, responses require 
a multidisciplinary approach to address the psychosocial 
aspects of drug-taking behaviours, in collaboration with 
healthcare professionals experienced in the management 
of sexual health problems. Research highlights the 
importance of screening and brief intervention, as well as 
effective referral processes to specialised drug treatment, 
as appropriate strategies to reduce harms related to drug 
use in this setting (Abdulrahim et al., 2016; Bourne et al., 
2015; PHE, 2015).
I NPS-related harms and deaths
In the absence of clinical trials establishing the physical 
and psychological harms caused by NPS consumption, 
this study relies on data from NPS hospital emergency 
presentations, post-mortem toxicology examinations 
reported by special mortality registers, fatal and non-fatal 
intoxications reported to the EU EWS, data from user 
surveys, regional and national poison information services, 
single-case or cluster reports and published scientific 
studies. In many cases it is almost impossible to assess 
the impact or role played by NPS compared with the 
impact of other substances, for example in acute 
emergencies or deaths where multiple substances are 
present.
I General acute NPS toxicity
A number of NPS may potentially cause acute intoxications 
leading to serious consequences, which might be 
aggravated in the context of high-risk drug use. 
Pharmacologically, these substances interact with various 
neurotransmitter targets affecting both the central and the 
peripheral nervous system.
Adverse effects linked with synthetic cathinones are 
similar to the monoamine dysfunction observed in 
stimulant (amphetamines, cocaine) users (EMCDDA, 
2011; German et al., 2014). The general pattern is 
characterised by agitation, paranoia, hallucinations, 
psychosis, myoclonus, headaches, hyperthermia, 
hypertension, tachycardia, hyponatremia, nausea, 
vomiting and chest pains (Capriola, 2013). In addition, 
stimulants such as ethylphenidate mimic the effects of 
the stimulant medicine methylphenidate and have been 
linked with a range of harms in the United Kingdom 
(ACMD, 2015; PHE, 2015). New synthetic opioids tend to 
produce the toxic effects typical of opioids such as heroin, 
including respiratory depression and respiratory arrest, 
loss of consciousness and coma, miosis, nausea, and 
drowsiness (EMCDDA, 2016a; Helander et al., 2016). 
Designer benzodiazepines produce the traditional 
benzodiazepines’ analogue sedative, hypnotic, anxiolytic 
and muscle-relaxant effects. Their combination with 
opioids potentiates the clinical features seen, including 
extreme sleepiness, respiratory depression, increased risk 
of overdose (Park et al., 2015), coma and death. SCRAs 
appear to have the potential for more severe and unusual 
effects than THC; in addition to the expected effects on 
the central nervous system, some SCRA compounds have 
been associated with stimulant-like features (including 
psychosis, seizures, tachycardia and autonomic 
hyperactivity), along with effects including kidney damage 
and suicidality (Gurney et al., 2014).
I Hospital emergencies and poisonings
Important insights into patterns and trends in acute health 
harms related to NPS use come from hospital emergency 
settings. Since 2013 the European Drug Emergencies 
Network (Euro-DEN) project has been collecting 
systematic data on the drug-related acute toxicity 
presentations to the emergency departments across 
Europe. Between October 2013 and September 2015, the 
original 16 sentinel centres in the Euro-DEN Plus network 
reported 10 956 emergency presentations directly related 
to the use of illicit drugs or NPS. Of these, 3 288 (30 %) 
involved the use of a substance potentially associated with 
high-risk drug use (buprenorphine, fentanyl, crack cocaine, 
heroin, methadone). Among these potential high-risk drug 
use cases, just 67 (2 %) involved the concomitant use of 
NPS. Looking at the characteristics of this small group, 
approximately 60 % of patients were male and the median 
age was 33 years. Their median stay in hospital was 13 
hours 30 minutes.
Almost all of the 67 cases were recorded in Munich, Dublin 
and London South (Figure 4). As shown in Figure 4, in the 
hospitals reporting higher proportions of NPS-using 
patients (Gdansk, York etc.), co-use of NPS was not 
necessarily common among those who had used high-risk 
drugs. In addition, other centres found no cases of co-use 
of NPS and high-risk drugs. Included in this group is York, 
where 30 % of the 405 presentations were related to NPS 
and a further 30 % were related to high-risk drugs. Also in 
the group are the Oslo centres, where the prevalence of 
NPS cases was less than 1 % and high-risk drugs 
accounted for 1 636 out of a total of 3 515 drug-related 
presentations. The types of NPS used along with high-risk 
established drugs varied between locations. Munich 
recorded presentations with synthetic cathinones and 
4-MPA. In Dublin, mephedrone was the only NPS used
alongside high-risk drugs.
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Some data are also available on national reports of acute 
intoxications sent to the EMCDDA and in the scientific 
literature. These indicate that a range of synthetic 
cathinones — MDPV, alpha-PVP, mephedrone and 
5-IT — were associated with acute intoxications in
Germany, Finland, Hungary, Poland, Sweden and the
United Kingdom between 2010 and 2015. Serious
intoxications associated with SCRAs have also been
reported to the EU EWS since 2015, including an outbreak
in the Polish Silesia region (483), as well as intoxications
in Sweden (10), Austria (7) and Germany (7) (EMCDDA
and Europol, 2016a). Sweden also reported a number of
acute intoxications linked to synthetic opioids between
2013 and 2015: MT-45 (12), AH-7921 (6) and
acetylfentanyl (6) (EMCDDA, 2014, 2015; EMCDDA and
Europol, 2016b).
I NPS-related infections: HIV and hepatitis C
People injecting stimulants report higher levels of 
sharing and reusing needles and syringes, of risky sexual 
behaviours, including unprotected sex, and increased 
numbers of sexual partners, resulting in an overall 
greater risk of acquisition and transmission of blood-
borne viruses, as well as injection site infections 
(Wiessing and Folch, 2016). People who inject 
stimulant-type NPS in particular synthetic cathinones 
are thus a population at risk of blood-borne viruses such 
as HIV, hepatitis C virus (HCV) and hepatitis B virus 
(HBV), linked to both sex and injection. The short 
duration of intravenous mephedrone action has been 
associated with repeat dosing and a high frequency of 
injection (10 to 20 times per day) to maintain and 
prolong the effects, leading to a higher risk of blood-
borne diseases and infections if infected injection 
equipment is shared. Besides compulsive use, other 
addictive elements such as craving, uncontrolled 
binging behaviours and withdrawal symptoms have 
been reported (German et al., 2014). In a recent analysis 
of slamming cases notified to the French Network of 
Addictovigilance, involving the injection of cathinones 
and other drugs among men who have sex with men, 
HIV prevalence was on average 82 %, with 50 % 
hepatitis C co-infection (Batisse et al., 2016).
Synthetic cathinone injection has been linked with 
increased HIV and HCV transmission in Ireland (Giese et 
al., 2015) and in the United Kingdom (Hope et al., 2016), 
and HCV transmission in Hungary (Horváth, 2013; Tarján et 
al., 2017). In the United Kingdom, Welsh services 
registered an increase in HCV and HIV infection rates 
among heroin users who were also using synthetic 
cathinones. In Ireland in 2015, an increase in the number 
of new HIV infections was reported among a group of 
homeless polydrug users who primarily injected alpha-PVP 
FIGURE 4
Hospital presentations related to NPS and co-use of NPS among high-risk drug presentations at Euro-DEN sentinel 
centres, October 2013 to September 2015
NPS use among all drug presentations Co-use of NPS among high-risk drug presentions
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(Giese et al., 2015). In Hungary in 2014, cathinone 
injection, mainly pentedrone, mephedrone, MDPV and 
alpha-PVP, was associated with HIV infection in people 
who inject drugs (Rácz et al., 2016). In addition, the 
injection of synthetic cathinones and sharing of needles 
have been identified as possible factors linked to recent 
outbreaks of HIV infection in Romania and Greece 
(Botescu et al., 2012; Fotiou et al., 2012).
I Physical harms and mental health problems
The high number of daily injections associated with the 
use of synthetic cathinones can also exacerbate a range 
of injection-related harms, including soft tissue injuries, 
abscesses, gangrene, sore or open wounds at injection 
sites, bacterial infections and vein clotting. In 2014 in 
Scotland (UK), an outbreak of soft tissue infections 
(Staphylococcus aureus and Streptococcus pyogenes) 
was associated with the injection of ethylphenidate, and 
in Slovenia, between 2014 and 2015, use of 3-MMC 
among intravenous opioid users was linked with soft 
tissue injuries. In addition, among a range of physical 
harms associated with NPS use, sleep deprivation and 
coordination problems were the most reported physical 
health problems in certain studies (MacLeod et al., 2016; 
Winstock et al., 2011). Some NPS have shown that they 
are potentially liable to produce physical and 
psychological dependence, tolerance and withdrawal 
(Baumeister et al., 2015). Other mental health problems 
are reported in the scientific literature, including 
psychotic reactions, self-harm, aggression, mood 
alterations and worsening of pre-existing psychiatric 
conditions.
Mephedrone consumption has been associated with 
increased risk of presenting psychotic symptomatology 
(delusive thoughts, hallucinations or disorganised speech). 
Although, in most cases, psychosis resolved within a few 
days, there have been reports of persistent psychotic 
symptoms for weeks after a single consumption 
(Dolengevich-Segal et al., 2016). The worsening of 
psychiatric status among high-risk drug users who started 
using synthetic cathinones and SCRAs has been reported 
in Germany, Finland, Hungary and the United Kingdom. 
Welsh drug services, for example, report that heroin users 
experienced rapid deterioration in mental and physical 
health after commencing NPS use, and many 
subsequently returned to using heroin.
Mental health problems, including self-harm, anxiety and 
depression, physical health problems and strong 
withdrawal effects are among the harmful consequences 
reported as linked to SCRA use in prisons.
I Social harms
Illicit drug use, particularly opioid use and injection, has 
historically been associated with social problems, and this 
is no less the case for NPS use. A number of sources 
highlighted social harms associated with the use of 
synthetic cathinones and SCRAs, including poverty, 
homelessness and challenges associated with users’ 
violence and aggression. In some countries (Czech 
Republic, Hungary and United Kingdom), NPS are 
increasingly being seen as the drugs of the poor. In 
Hungary, the use of SCRAs is particularly linked with rural 
poverty. In the United Kingdom, the use of SCRAs among 
homeless people and marginalised youth has been high on 
the political agenda in recent months (MacLeod et al., 
2016). Slovenia also reports the use of 3-MMC among 
marginalised populations including vulnerable young 
people and sex workers.
In Ireland, three Dublin drug treatment services have 
reportedly closed (and later reopened) because of problems 
dealing with synthetic cathinone users (mephedrone and 
alpha-PVP) and management of difficult client behaviour 
(e.g. severe agitation, aggression and violence in users). 
Similarly, a number of Europe’s prisons are struggling with 
behavioural challenges among inmates. As discussed 
earlier, the growing level of NPS use in prisons in Europe 
may be linked to an increasing level of violence towards 
both prisoners and staff (User Voice, 2016).
I NPS-related deaths
Across European countries the number of deaths where 
NPS are involved in the context of high-risk drug use is 
variable and difficult to establish. In particular, there are 
many limitations in the data on drug-related mortality. 
These include the likely under-detection and 
underreporting of NPS in post-mortem analysis, especially 
when heroin or other illicit drugs are also present. Also, 
lack of specific codes for NPS in general mortality registers 
prevents many NPS-related fatal poisonings from being 
identified. An unknown number of NPS-related deaths may 
be hidden behind cases associated with heroin, other 
opioids or stimulants.
A limited number of deaths among high-risk drug users 
have been associated with synthetic cathinones in Europe. 
Between 2010 and 2014, Finland, Sweden and the United 
Kingdom reported deaths due to synthetic cathinone use, 
in addition to cases where these drugs were present in the 
post-mortem toxicology together with other substances 
such as alcohol and medicines. Synthetic cathinones that 
have been associated with deaths in Europe include 
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MDPV, alpha-PVP, mephedrone, 4,4′-DMAR and 5-IT 
(5-(2-aminopropyl)-indole). SCRAs have also been linked 
with deaths. For example, between 2012 and 2014, the 
United Kingdom reported 19 deaths in prison in which 
SCRAs were suspected to have played a role; Hungary, 
Sweden and Turkey have also reported SCRA deaths.
Although numbers remain low, deaths in Europe related to 
new synthetic opioids have been reported to the EU EWS. 
These substances can be extremely potent, and very small 
doses can cause fatalities. Derivatives of fentanyl, such as 
ocfentanyl and acetylfentanyl, have contributed to 
a number of deaths in Belgium, Germany, Poland, Sweden 
and the United Kingdom. Other new synthetic opioids have 
also been associated with morbidity. More than 40 deaths 
were reported to the EMCDDA within months of the 
detection of the opioids AH-7921 and MT-45 on the 
European drug market. In 2016, new dangerous synthetic 
opioids have been detected, with 23 deaths in Sweden 
linked to acryloylfentanyl and four deaths in Finland linked 
to U-47700.
Other NPS, such as tryptamines — which are known for their 
hallucinogenic properties — have been associated with fatal 
intoxications in Europe. However, these substances are 
rarely linked to high-risk drug-using populations and are 
primarily reported in recreational contexts. In Scotland, in 
2015, NPS were implicated in 74 deaths, with three where 
NPS were the only substance present. The NPS most 
commonly implicated in these 74 deaths were 
benzodiazepine-type NPS such as phenazepam, etizolam 
and diclazepam (MacLeod et al., 2016).
I Motivations for use
The reasons behind new outbreaks of NPS use among 
high-risk drug users and the emergence of clusters of 
problematic use of NPS are variable and complex. 
Nevertheless a few common factors can be identified, 
including reduced availability of illicit drugs, competitive 
prices, the fact that NPS are hard to detect in routine drug 
tests, their legal status and specific qualities of the 
substances themselves.
Most evidence on motivation for use of NPS comes from 
studies of recreational users and the general population. An 
examination of motivational characteristics of each group 
of NPS (i.e. SCRAs, opioids, hallucinogens, dissociatives 
etc.) revealed that price, legal status, availability and 
non-detectability in screening tests acted as motivation for 
use of SCRAs more than for hallucinogens, stimulants and 
dissociatives (Soussan and Kjellgren, 2016). Research on 
the first wave of mephedrone use in the United Kingdom 
and Ireland (early 2009) suggested that their uptake by 
experienced drug users might be due to the reduced 
availability and low purity of ecstasy pills and powder 
cocaine (Measham et al., 2010).
Research on synthetic cathinones and the use of 3-MMC 
in Slovenia identified that low price and high purity were 
among the most important reasons for use and more 
important than legality of NPS and lack of traditional drugs 
(Sande, 2016). Conversely, findings from a German online 
survey (Werse and Morgenstern, 2012) identified legality 
as a major incentive for the use of SCRAs.
There is even less evidence to explain the emergence of 
NPS use among high-risk drug users in Europe. 
Nevertheless, in Hungary and the United Kingdom, use by 
this group has been linked to shortages of heroin in 
2010/11 (Griffiths et al., 2012). In particular, ready 
availability and the low price of mephedrone and other 
cathinones are documented as reasons. The push factors 
behind use of mephedrone by men who have sex with men 
in chemsex contexts appear linked to both availability 
factors and the empathogenic effects of the drug (Amaro, 
2016), alongside the emergence of dating websites and 
phone apps aimed at men who have sex with men.
A 2016 study found that Scottish users were motivated to 
continue using NPS by its ease of access, pleasure, 
compulsion, a desire to avoid going into withdrawal, and as 
a way to self-manage underlying mental health problems 
or dependency (MacLeod et al., 2016). The same study 
revealed that the motivations of users to stop using NPS 
were related to ‘not liking’ them or to specific harms that 
individuals had experienced such as negative impacts on 
mental and physical health. Legal status did not appear to 
be a key motivator for use. Conversely, the use of SCRAs 
by treatment clients to avoid drug tests was highlighted by 
German experts participating in the EMCDDA study.
Some of the motivations identified for NPS use among 
recreational populations may be less important for 
high-risk drug users. For example, the legality issue is less 
significant for people who are already using a range of 
other, illicit, substances. Online availability may not be 
directly beneficial for many marginalised and homeless 
users, who will be most likely to source their supply of 
substances from street dealers. However, the fact that 
SCRAs are difficult to detect in drug tests will be a major 
pull factor, for example among prisoners. Low price 
(cheaper than alcohol) and ready availability are both 
factors linked to use among low-income groups, and have 
been cited as reasons for rapid uptake of SCRAs among 
homeless populations in the United Kingdom, and Roma 
communities in Hungary and Finland.
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I Discussion
I Top-level trends and developments
This analysis has focused on a new and emerging drug use 
problem. However, the small scale of the phenomenon is 
important to remember. To put things into perspective, the 
latest estimates are that there are around 1.3 million 
high-risk opioid users in Europe, most of whom use heroin 
(EMCDDA, 2017). There were also an estimated more than 
8 400 drug-induced deaths in 2015, most related to heroin, 
methadone, cocaine and amphetamines. Some of these 
high-risk users will also include NPS in their repertoire, 
either regularly or occasionally. Indeed, this analysis 
suggests that primary NPS users are very rare and that 
most problem use of NPS occurs in the context of 
polysubstance use. Only use of SCRAs by prisoners and 
homeless populations appears to be less linked with other 
high-risk drug use patterns, although it is probably 
connected with alcohol and cannabis use.
At least among pockets of drug users in many European 
countries, it seems reasonable to state that the distinction 
between the use of established substances and NPS is 
diminishing. This is occurring in a situation characterised 
by rather fluid patterns of polydrug use closely meshed 
with substance availability, price and purity. In a number of 
countries, NPS are now more visible and important than 
chronic and more problem patterns of substance 
consumption. There are, however, some qualifiers and the 
picture is not a simple one. For a number of countries, 
mainly situated in the south of Europe, very little NPS use 
is reported. For another group of countries, a low level of 
problem NPS use has been identified, while for a small 
group of countries, notably Hungary, Ireland and the United 
Kingdom, this is a major issue for drug policy and 
a challenge for health and social responses. At least for 
these countries, there appear to be some common drivers, 
including diminishing heroin supplies and ready availability 
of NPS, first through shops and later through online 
means. Common protective factors for countries with little 
or no evidence of this problem may include plentiful 
access to other illicit substances, in particular stimulants 
(cocaine and methamphetamine) and cannabis.
I Tribes, clusters … and implications for harm
This analysis has highlighted diverse NPS-using populations 
and contexts for use in Europe. The populations identified 
as involved in high-risk use of SCRAs and synthetic 
cathinones range from very young experimenters (e.g. 
Finland, Slovenia) and young marginalised or disaffected 
populations (Hungary, United Kingdom) to older polydrug 
users and high-risk stimulant users. A common thread is 
social vulnerability; in most cases we are talking about small 
groups of users in many cases these are socially 
marginalised populations, often unemployed and homeless, 
sometimes with coexisting mental health disorders and 
established criminal careers. Also highlighted are patterns 
Most NPS and precursors are produced in China and 
bought by European distributors, often in bulk quantities, 
and transported to Europe by air or sea. European 
actors, often with links to organised crime, then package 
and market them either on the open market or directly 
on the illicit drug market. For small quantities, online 
orders may be placed directly with Chinese vendors or 
via internet smart shops. Orders are then shipped using 
the postal service and couriers (delivery companies).
Both online and bricks-and-mortar shops have been 
important sales platforms for new substances in 
Europe. In particular the internet plays an important role 
for NPS distribution (Soussan and Kjellgren, 2016) and 
its ease of access reaches geographically remote areas. 
Substances are typically marketed as research 
chemicals, dietary supplements or plant food, and 
commonly labelled ‘not for human consumption’ to 
circumvent drug control legislation. Dark net markets 
also provide anonymity for operators and a similar 
infrastructure for sellers and buyers of NPS to those 
provided by other online marketplaces (e.g. eBay or 
Amazon). Once substances have been controlled, 
however, they have also been increasingly supplied by 
traditional sources such as street dealers.
The synthesis of many NPS requires similar equipment 
and chemical expertise to those needed for the 
manufacture of illicit synthetic drugs. In a relatively 
recent development, market signals suggest an 
increase in the production and importation of 
precursors that can be used for the synthesis of NPS 
within Europe, for European markets (EMCDDA, 2016b; 
Europol, 2013).
NPS production, distribution and marketing
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of NPS use among minority groups, including Roma 
communities, and geographically isolated populations, both 
rural and urban poor. In some cases, NPS use is integrated 
into the drug use repertoires of people who inject drugs in 
open urban drug scenes. However, our analysis shows that 
the settings in which high-risk NPS use occurs vary 
considerably, including penal institutions, where SCRAs 
may be preferred by those subject to drug testing, and 
house parties, where mephedrone is used in the context of 
chemsex and slamming.
This study highlights the need for a strong public health 
response targeted at people using NPS in a problematic 
way, and tailored specifically to their needs. A particular 
concern is the lack of appropriate treatment and harm 
reduction (including drug checking) services available for 
users experiencing problems with stimulants and SCRAs. 
The fact that much NPS use occurs among marginalised 
and hard to reach groups (socially and geographically) has 
implications for the delivery of appropriate responses. 
Responding to problems associated with acute toxicity is 
a clear challenge, while health problems arising from 
chronic toxicity remain a potentially important future issue. 
Issues including increased injecting and increased 
injecting-related risk behaviours have been highlighted as 
causes for concern. It is evident that the whole area of sex 
and use of stimulant drugs has not been well explored, 
including use among male and female sex workers. This 
analysis has also highlighted reports of particularly chaotic 
clients, with high levels of aggression and psychiatric 
comorbidity, who are harder to engage in treatment. 
Importantly, greater interaction is needed between drug 
services and other health and social intervention providers 
including housing, homelessness, sexual health and 
mental health services.
I Great variation in patterns of use across Europe
The study findings highlight a dynamic and rapidly 
changing NPS landscape in Europe with extensive national 
and local variability in both substances used and problem 
user groups involved.
To a certain extent, pan-national patterns or clusters can 
be identified. For example, Hungary, Ireland and the United 
Kingdom report similar trends, all with a history of 
intravenous cathinone use developing among clusters of 
opioid users in the wake of the heroin shortages reported 
in 2010/11. In these countries, trends may have peaked 
around 2015, and cathinones are integrated into polydrug 
use and injecting patterns involving opioids, 
amphetamines (including ethylphenidate) and 
benzodiazepines.
At the national level, different substances appear to be 
available and used, and this is particularly evident for the 
cathinones. For example, this study found 3-MMC in 
Slovenia, pentedrone in Hungary, mephedrone in Wales 
and alpha-PVP in Finland. Availability is clearly a push 
factor here and the market shift from one cathinone to the 
next is well illustrated by the Hungarian syringe residue 
analysis, which documents how the changing use patterns 
may be linked to the introduction of control measures.
Northern European countries seem disproportionately 
affected by new synthetic opioids. While in part this may 
be put down to strong forensic reporting capacity in these 
countries, there may also be cultural factors at play, 
including some historical use of fentanyl and derivatives in 
the region. Equally of note, most southern EU countries 
have relatively few reports of NPS use and harms among 
high-risk drug users, and the reasons for this, whether 
related to reporting or more linked to protective factors 
such as good access to established illicit drugs, would 
certainly warrant further exploration in the future.
Wide variations in patterns of use were also highlighted 
within countries. For example, in Germany, high-risk use of 
NPS appears to be primarily restricted to Munich and 
Bavaria, and was not picked up as a problem in other cities. 
Hospital emergency data from Euro-DEN also confirm this 
city-level variability. The sophisticated work undertaken on 
syringe residue analysis in French cities (Néfau et al., 
2015) is able to identify the use of different NPS at the 
local level, differentiating use profiles for small 
geographical areas where injecting equipment is collected.
I How have things changed
This analysis served to highlight some of the fast-moving 
changes witnessed in Europe’s NPS market, most of which 
have occurred since around 2010. Although this is a very 
crude simplification, a number of trends can be highlighted. 
In terms of NPS supply, we have seen a move from sale of 
predominantly ‘legal’ products in shops, whose emergence 
coincided with poor availability and quality of established 
drugs, to the current situation, which includes organised 
crime groups’ involvement in the distribution of (often 
controlled) NPS, which are frequently sold alongside 
established drugs. By comparison with 2010, the purity and 
availability of established illicit drugs is now reportedly 
improved in many countries (EMCDDA, 2016b). In terms of 
product reputation, there has been a gradual shift from 
NPS being considered safer and weaker than established 
illicit drugs to being viewed as potentially more harmful and 
potent. NPS users at the time of mephedrone’s emergence 
in 2010 were primarily young and neophyte, non-
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marginalised experimenters, linked with recreational 
settings. Currently the spotlight is on more marginalised 
groups, experienced polydrug users and injectors, and the 
substances used in many arenas. Finally, there is some 
evidence of a shift in the role of NPS, which in the early 
days were seen largely to be a replacement for cannabis or 
recreational stimulants. In the current marketplace we see 
NPS also serving as replacements for opioids, sedatives 
and dissociatives. Today’s SCRAs are probably much less 
likely to be used as a cannabis replacement, at least among 
more experienced users.
There are a number of possible drivers of the NPS 
phenomenon and its gradual spread among vulnerable 
user groups, although it is not clear what combination of 
supply or demand factors lie behind different availability 
patterns and clusters of problem NPS use and have been 
fuelling them.
The role played by globalisation and developments in 
information technology have clearly been central for the 
spread of NPS but are harder to pin down for high-risk drug 
use. Countries with aggressive drug control policies may be 
susceptible to the spread of legal alternatives to illicit drugs, 
yet, in a number of cases, prison appears to play a role as 
initiation vector to NPS use, in particular SCRAs. A number 
of questions also remain unanswered. Why has NPS use not 
happened in some countries? Is this merely a recording 
issue, or more related to sociocultural factors, drug markets, 
patterns of historical drug use or perhaps different law 
enforcement environments? Are NPS substitutes or 
supplements for existing illicit drugs, or both?
I Definition and data: two linked problems
This study has highlighted a number of underlying 
problems associated with monitoring both the availability 
and use of NPS and the area of problem or high-risk drug 
use. In the first instance it is clear that existing definitions 
have proved unfit for purpose when exploring the area 
covered by this analysis. We opted to use a broad and 
inclusive understanding of high-risk drug use for this 
study in order to ensure that the boundaries were 
sufficiently wide to incorporate potential new problem 
patterns of use or at least those outside our current 
monitoring gaze. Nevertheless, there is clearly a need for 
further clarification, and the old and rather crude 
dichotomy of recreational and problem drug use and drug 
users does not make sense when looking at a complex 
and graduated theme such as high-risk forms of NPS use. 
The decline of the injecting heroin user as the norm for 
high-risk drug users is a major factor perpetuating the 
dissolving of clear definitional understandings. A range of 
patterns of drug use behaviours — injecting, frequent, 
heavy, chronic, high-risk and harmful — have been 
identified as linked with NPS use and related problems. In 
particular, the slammers, prisoners, homeless people and 
at-risk young people using NPS may easily be left out of 
a narrower problem drug use monitoring definition, and 
importantly we would have missed these ‘edges’ of the 
problem if we had kept to a narrow categorisation. What 
has been identified here is a more fluid situation, with 
polydrug consumption patterns and stimulant drugs 
seemingly playing a more central role than previously. 
Linked with these patterns of use are differing dimensions 
of harm, which provide an alternative point of focus. Here 
there are diverse acute and chronic health problems, 
social harms and dependence, and interactions between 
all areas.
The challenges are no less evident when it comes to 
pinning down a useful definition of NPS for our purposes. 
In the first place, NPS is an ill-defined term, with a formal 
legal definition that, while necessary for identification 
and control purposes, is less useful for exploring 
emerging epidemiological patterns of use and harms. 
Again, this analysis utilised a generous and broad 
definition, bearing in mind the fact that the focus includes 
30 countries with different sets of NPS laws and 
regulations, and where the control status of substances 
will be constantly changing. Accordingly, several relatively 
old NPS such as mephedrone and MDPV feature quite 
heavily. The area of misuse of medicinal products and the 
crossover with NPS complicates matters further, in 
particular with regard to new synthetic opioids, where for 
example fentanyl is categorised as a medicine but 
a range of new fentanyl derivatives come under the NPS 
umbrella. Similarly, new benzodiazepines are clearly 
a major problem in some countries, and online sale of 
these substances is likely to increase their availability and 
consumption in the future.
Another tricky aspect of monitoring and researching NPS 
is the challenge linked to use of an umbrella term, with 
multiple drugs grouped together under a single heading. 
What may have been a useful categorisation a decade ago, 
at the start of this new market phenomenon, is now largely 
obsolete for the practical purposes of exploring patterns of 
use and harm. It is unlikely that anyone will self-identify or 
be usefully identified as an NPS user per se (never mind 
the fact that NPS are almost never a primary reported 
drug). At the user level, the street names — meph, 
snowblow, bath salts, spice — may be the most common 
identifiers, while, for purposes of understanding effects 
and harms, health professionals are more likely to find the 
generic categories of SCRAs, synthetic opioids and 
synthetic cathinones somewhat more helpful.
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This situation is further complicated by the rapid pace of 
change. While the small number of NPS identified in 
2008–10 largely comprised a few cathinones and 
cannabinoids finding their way onto the European market 
as legal alternatives to cannabis, MDMA and cocaine, the 
current situation is very different. We now have a third 
generation of SCRAs, a wide variety of cathinones, 
increasing numbers of very potent synthetic opioids 
appearing, and a range of medicinal NPS on the illicit 
market. Finally, problems are compounded by the 
availability of NPS in mixtures (PMMA with MDMA, 
fentanyl with heroin), some of which have been combined 
on purpose to increase potency, while others may be 
accidental occurrences.
I Dearth of data and implications for monitoring
This is also an area where access to data and the data 
itself are a particular problem. Not only are few data 
available, but many of them are lagged, and we are 
particularly reliant on expert opinion and self-reports with 
a lack of forensic confirmation. Matters are further 
complicated by the high degree of temporal and 
geographical variation between and within countries. In 
addition, there have been in the past very small, localised 
outbreaks related to some drugs that have emerged and 
then completely disappeared. In theory at least, there 
should be routine data available on drug users already in 
contact with helping services, via treatment entrance, for 
example. However, a number of subpopulations identified 
in this analysis are evidently not in touch with traditional 
drug services and thus may be missed, both by monitoring 
systems and by health and social interventions. In 
particular, rural poor communities, slammers, homeless 
people and prisoners might all rather easily slip under the 
net. This is therefore an area where the so-called 
‘lamppost problem’ may operate, with investigators and 
helpers alike seeing only what they are looking for and not 
what lies outside their immediate remit.
Monitoring of high-risk or problem drug use continues to 
be challenging, and epidemiological surveillance of NPS 
use is very much in its infancy in many countries. 
Looking at high-risk forms of NPS use is therefore 
always going to be a difficult endeavour. This wide-
ranging investigation nevertheless confirms the 
importance of extending monitoring activity to embrace 
new substances, new populations and in some cases 
new technologies. The use of proactive approaches 
(residue testing, outreach) and open source and online 
monitoring will undoubtedly play an important role in the 
future.
Some of the emerging phenomena identified here have 
a global/local nature, for example slamming, which 
appears to be subcultural and metropolitan rather than 
a national phenomenon. This is also an area where 
information gathered at the local and city level helps 
inform our understanding and where in the future a model 
of information communities (multi-source/mutual benefit) 
might be well applied. Finally, it is important that 
toxicological and forensic information services continue to 
identify and warn of potentially potent new substances 
such as fentanyls and other new synthetic opioids.
I Conclusion: an uncertain future
This analysis has demonstrated that problem use of NPS 
in Europe is currently linked with relatively small numbers 
of users but high associated levels of harm. It confirms and 
further maps the documented use of synthetic cathinones 
by pockets of opioid injectors and among slammers, while 
bringing to light new trends in SCRA use among prisoners 
in over a third of EU countries as well as developments 
among marginalised communities. It remains unclear, 
however, how and why SCRAs are becoming established 
as the cheapest and strongest indiscriminate intoxicants in 
some vulnerable social groups. Questions also remain 
about how this trend might play out in the longer term, and 
which of those NPS now present on the market will remain 
and become established. At a time when the distinction 
between the use of illicit drugs and NPS may be 
diminishing, highly potent new synthetic opioids appear to 
be emerging. Use of these is often unintentional, they raise 
particular concerns for public health, and fear of these 
substances is reportedly strong among users. Important 
questions to explore in the future include: will the use of 
new synthetic opioids, with their high potency and online 
availability, become more widespread; and will new 
benzodiazepines become more popular? Recent 
indications that NPS production may now be taking place 
in Europe are potentially a game changer, and provide 
strong motivation to keep a close watch on emerging 
trends in this rapidly evolving area.
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